Cyclosporine oral 25 mg
Products billed under this code include Cyclosporine, Gengraf, Neoral, Sandimmune.
Payment limit per 25 MG, by effective quarter, 1Q21 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.Products billed under this code include Cyclosporine, Gengraf, Neoral, Sandimmune.
Payment limit per 25 MG, by effective quarter, 1Q21 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.From the 4Q26 NDC–HCPCS crosswalk. “Limit / pkg” is the 4Q26 payment limit times the billing units in one package.
| Product | Labeler | NDC | Units / pkg | Limit / pkg |
|---|---|---|---|---|
| Cyclosporine | Teva Pharmaceuticals USA, Inc. | 00093-9018-65 | 30 | $17.28 |
| Cyclosporine | Heritage Pharmaceuticals Inc. | 23155-0837-30 | 30 | $17.28 |
| Cyclosporine | Heritage Pharmaceuticals Inc. | 23155-0838-30 | 60 | $34.56 |
| Cyclosporine | Apotex Corp | 60505-0133-00 | 30 | $17.28 |
| Cyclosporine | Apotex Corp | 60505-4630-03 | 30 | $17.28 |
| Cyclosporine | Apotex Corp | 60505-4631-03 | 60 | $34.56 |
| Cyclosporine | American Health Packaging | 68084-0879-25 | 30 | $17.28 |
| Gengraf | AbbVie Inc. | 00074-3108-32 | 30 | $17.28 |
| Neoral | Novartis Pharmaceuticals Corporation | 00078-0246-15 | 30 | $17.28 |
| Sandimmune | Novartis Pharmaceuticals Corporation | 00078-0240-15 | 30 | $17.28 |
| Quarter | Payment limit | Change | Billing unit | Description | Source file |
|---|---|---|---|---|---|
| 4Q26 | $0.576 | +$0.024 | 25 MG | Cyclosporine oral 25 mg | v1, posted September 17, 2026 |
| 3Q26 | $0.552 | −$0.074 | 25 MG | Cyclosporine oral 25 mg | v1, posted September 15, 2026 |
| 2Q26 | $0.626 | +$0.10 | 25 MG | Cyclosporine oral 25 mg | v1, posted September 15, 2026 |
| 1Q26 | $0.526 | −$0.276 | 25 MG | Cyclosporine oral 25 mg | v1, posted September 15, 2026 |
| 4Q25 | $0.802 | +$0.033 | 25 MG | Cyclosporine oral 25 mg | v1, posted September 8, 2026 |
| 3Q25 | $0.769 | +$0.027 | 25 MG | Cyclosporine oral 25 mg | v1, posted March 10, 2026 |
| 2Q25 | $0.742 | −$0.084 | 25 MG | Cyclosporine oral 25 mg | v1, posted March 10, 2026 |
| 1Q25 | $0.826 | −$0.021 | 25 MG | Cyclosporine oral 25 mg | v1, posted December 19, 2025 |
| 4Q24 | $0.847 | +$0.052 | 25 MG | Cyclosporine oral 25 mg | v1, posted June 11, 2025 |
| 3Q24 | $0.795 | −$0.126 | 25 MG | Cyclosporine oral 25 mg | v1, posted June 11, 2025 |
| 2Q24 | $0.921 | +$0.084 | 25 MG | Cyclosporine oral 25 mg | v1, posted March 11, 2025 |
| 1Q24 | $0.837 | +$0.152 | 25 MG | Cyclosporine oral 25 mg | v1, posted December 19, 2024 |
| 4Q23 | $0.685 | −$0.069 | 25 MG | Cyclosporine oral 25 mg | v1, posted October 10, 2024 |
| 3Q23 | $0.754 | +$0.009 | 25 MG | Cyclosporine oral 25 mg | v1, posted June 5, 2024 |
| 2Q23 | $0.745 | +$0.038 | 25 MG | Cyclosporine oral 25 mg | v1, posted February 23, 2024 |
| 1Q23 | $0.707 | +$0.049 | 25 MG | Cyclosporine oral 25 mg | v1, posted December 6, 2023 |
| 4Q22 | $0.658 | −$0.12 | 25 MG | Cyclosporine oral 25 mg | v1, posted June 22, 2023 |
| 3Q22 | $0.778 | +$0.032 | 25 MG | Cyclosporine oral 25 mg | v1, posted June 9, 2023 |
| 2Q22 | $0.746 | −$0.122 | 25 MG | Cyclosporine oral 25 mg | v1, posted December 14, 2022 |
| 1Q22 | $0.868 | +$0.047 | 25 MG | Cyclosporine oral 25 mg | v1, posted June 8, 2022 |
| 4Q21 | $0.821 | +$0.244 | 25 MG | Cyclosporine oral 25 mg | v1, posted June 2, 2022 |
| 3Q21 | $0.577 | −$0.044 | 25 MG | Cyclosporine oral 25 mg | v1, posted June 2, 2022 |
| 2Q21 | $0.621 | −$0.021 | 25 MG | Cyclosporine oral 25 mg | v1, posted March 1, 2022 |
| 1Q21 | $0.642 | – | 25 MG | Cyclosporine oral 25 mg | v1, posted December 10, 2021 |
“Change” is the difference from the previous quarter, shown only when both quarters have a payment limit and the billing unit is the same. “vs. last quarter” and “vs. a year ago” follow the same rule.